NICE’s health inequalities modular update: Commentary on NIC...
NICE’s modular update on health inequalities, consulted on in January and finalised in May, has now been incorporated into its manual.1 A total of 26 individuals and organi
When is the superbug message going to bite?
As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.
Liver cancer diagnostic gets FDA breakthrough status, with P...
Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.
FDA clears new, safer regimen for Lilly's Alzheimer's drug
Eli Lilly has won FDA approval for a new regimen for its Alzheimer's disease therapy Kisunla, which carries a reduced risk of side effects.
Featured Content
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
2nd Autoimmunity & Inflammation Partnering & Investment Summ...
Driving deal-making across targeted cell depletion, checkpoint agonism, tolerance, and oral anti-inflammatory biologics...
Welcome to the 2nd Raw Materials for Cell & Gene Therapy Sum...
Streamline Supply Chain Communications to Optimize Phase Appropriate QC Testing, Comparability & GMP Manufacturing of Raw Materials...
Network With EHS Professionals - EHS&S for Biopharma West
Advancing Biosafety & Sustainability in R&D & Manufacturing
The World's Definitive Degrader & Proximity-Based Drugs Even...
The 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities
Welcome to the 7th Exosome-Based Therapeutic Development Sum...
Accelerate Therapeutic Efficacy & Delivery Potential of Exosomes & EVs